Journal
CLINICAL CANCER RESEARCH
Volume 20, Issue 11, Pages 2817-2819Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-14-0576
Keywords
-
Categories
Funding
- Department of Defense Prostate Cancer Research Program postdoctoral training award [PC101890]
- Jerry and Peggy Throgmartin Endowment
- Indiana Economic Development Fund
- National Cancer Institute (NCI/NIH) [R01-CA69158, U01-CA143057]
- V-Foundation
- Susan G. Komen Foundation
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS/NIH) [R01-AR059221]
Ask authors/readers for more resources
Factors released during osteoclastic bone resorption enhance disseminated breast cancer cell progression by stimulating invasiveness, growth, and a bone-resorptive phenotype in cancer cells. Postmenopausal bone loss may accelerate progression of breast cancer growth in bone, explaining the anticancer benefit of the bone-specific antiresorptive agent zoledronic acid in the postmenopausal setting. (C) 2014 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
